Revenue - Additional Information (Details) $ in Thousands	3 Months Ended
Mar. 31, 2021 USD ($) dose	Dec. 31, 2020 USD ($)
Revenue Recognition
Deferred revenue ending balance \| $	$ (822,809)	$ (273,228)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-04-01
Revenue Recognition
Amount of transaction price not yet satisfied \| $	$ 5,000,000
Revenue, remaining performance obligation, expected timing of satisfaction, period	12 months
Advance Purchase Agreements - Canada
Revenue Recognition
Number of doses of the vaccine \| dose	52,000,000
Deferred revenue ending balance \| $	$ (772,000)
Additional purchase option \| dose	24,000,000
SK Bioscience Agreement
Revenue Recognition
Number of doses of the vaccine \| dose	40,000,000

Represents the number of doses of the vaccine candidate, NVX-CoV2373.

No definition available.

Name:	nvax_NumberOfDosesOfVaccineCandidate
Namespace Prefix:	nvax_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Doses Of Vaccine Candidate, Additional Purchase Option

+ References

No definition available.

+ Details

Name:	nvax_NumberOfDosesOfVaccineCandidateAdditionalPurchaseOption
Namespace Prefix:	nvax_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(5))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_DeferredRevenueCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2021-04-01
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=nvax_AdvancedPaymentAgreementCanadaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=nvax_SKBioscienceAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: